DexCom's key Q3 earnings factors include Stelo sales, updates on sales channels, and potential share buybacks. See why I ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

DexCom's newest G7 CGM competes closely with Abbott's FreeStyle Libre 3, both products have very similar features and design innovations. DexCom's forward multiples suggest the company is trading ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

SAN DIEGO, September 18, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third ...

A top healthcare stock to own over the years has been DexCom (NASDAQ: DXCM). The company makes continuous glucose monitors ...

Today, DexCom is the leading CGM company, with an estimated 40% market share. Importantly, CGM products are relatively nascent. DexCom generates nearly $4 billion in annual sales on a user base of ...

Strong Product Demand: We are upbeat about DexCom's continued strength in its CGM products. The company continues to expand its product portfolio with the addition of new products like G7 in 2023 ...

The International Longshoremen’s Association strike is a test of whether unions can push back against a wave of automation ...

At its current valuation, DexCom stock is the opposite of a bargain. Even after its big drop over the summer, it would still be a risky stock to buy now. Those who are interested would probably do ...

Dexcom unveiled its Dexcom G7 continuous glucose monitoring (CGM) for people with diabetes age two years and older in Australia. The Dexcom G7 is a wearable and sends real-time glucose readings ...

Jessica is a writer on the Wellness team with a focus on health technology, eye care, nutrition and finding new approaches to chronic health problems. When she's not reporting on health facts, she ...